AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05144750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fruit and Vegetable Prescription
Description: The intervention adds a $50 monthly fruit and vegetable voucher, and text reminder and educational text messages (recipes/tips) to the Standard of Care for patients.~Standard Care for Patients at OCH: Patients will be able to regularly meet with their healthcare team.~Fruit and Vegetable Incentive: During the 8-month intervention period, registered program participants can receive $50 monthly through the reloadable Walmart gift card, which can only be used to purchase fresh fruits and vegetables. The total incentive will be $400 for the eight-month program.~Text Communication: Wholesome Wave will share text reminders to shop and utilize incentives. Wholesome Wave will also share text messages that are consistent with the messages that the OCH dietitians are offering in their standard care, including recipes and tips.
Study NCT05267275 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extended resection with splenic flexure mobilization
Description: During the operation, the splenic flexure of the colon was first freed, and then the physiological adhesion site of the sigmoid colon was located. Routine laparoscopic or open rectal cancer radical resection (D3 dissection + high ligation) was performed. The proximal end of the colon is disconnected 10-15cm away from the physiological adhesion site of the sigmoid colon. The anastomosis method was manual anastomosis or stapler anastomosis, and a prophylactic ileal loop ostomy was routinely performed.
Study NCT04664361 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide mononucleotide
Description: Daily supplementation with NMN at 250 and 500 mg for 38 days in total
Study NCT04664361 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily supplementation with placebo for 38 days in total
Study NCT05914636 — intervention group
Intervention type: BIOLOGICAL
Intervention: analysis of foecal microbiota
Description: An analysis of foecal microbiota including taxonomic and metabolomic analysis will be performed and compared between ruptured and unruptured patient.~confundens factors as diet, obesity for microbiota and as smoking, hypertension, size for aneurysm ruptured will be sampled and independence will be analyzed.
Study NCT05501561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: IIV-A Investigational IIV-A will be administered as a single dose intramuscularly on Day 1
Description: Biological/Vaccine: Investigational IIV-A Investigational Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study NCT05501561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1
Description: Biological/Vaccine: Investigational aIIV-B Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study NCT05501561 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental: aIIV-C Investigational aIIV-C will be administered as a single dose intramuscularly on Day 1
Description: Biological/Vaccine: Investigational aIIV-C Investigational MF59 Adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study NCT05501561 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Licensed IIV IIV will be administered as a single dose intramuscularly on Day 1
Description: Biological/Vaccine: Licensed IIV Licensed Non-adjuvanted Quadrivalent Influenza vaccine, containing four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata and Victoria lineage) recommended by the WHO (World Health Organization) for quadrivalent vaccines for the respective season.
Study NCT04945070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGlarLixi
Description: Switching T2DM subjects from MDI to iGlarLixi
Study NCT04945070 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDI - Multiple dose insulin injection
Description: Continuing with established MDI regimen
Study NCT06255704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib and RCHOP/RDHAP
Description: Alternating 3× R-CHOP/ 3× R-DHAOx, every 21 days plus oral Zanubrutinib in cycle 1, 3, 5 in combination with R-CHOP:~R-CHOP (cycle 1,3,5):~Rituximab 375 mg/m2 D1, I.V. Cyclophosphamide 750 mg/m2 D1, I.V. Doxorubicine 50 mg/m2 D1, I.V. Vincristine 1.4mg/m2(max 2mg)D1, I.V. Prednisone 100mg D1-5, oral Zanubrutinib 160mg BID D1-21, oral~R-DHAP(cycle 2,4,6):~Dexamethasone 40mg D1-4 oral/I.V. Rituximab 375mg/m2 D1, I.V. Ara-C 2×2g/m2 q12h D2, I.V. Cisplatin 100mg/m2 D1, I.V.~Maintenance:~Zanubrutinib, 160mg PO BID, rituximab 375mg/m2 repeated every 8 weeks, treatment will continue for up to 2 years or until progressive disease。
Study NCT05246436 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: warming saline media
Description: use warm saline as a distention media in office hysteroscopy
Study NCT05246436 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: room temperature saline media
Description: use room temperature saline as a distention media in office hysteroscopy
Study NCT06535243 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifespan Integration Therapy (LI)
Description: same as above
Study NCT05074251 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV self test
Description: For women allocated to the intervention arm, the participant will be given HIV self testing and counseling on their use \& importance of partner testing, to take home to their partner(s).
Study NCT05074251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling and referral for partner testing
Description: Counseling and refer participant's partner for facility based HIV testing
Study NCT05074251 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling and referral for partner testing
Description: Counseling and refer participant's partner for facility based HIV testing
Study NCT04658901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERA-C70,ERA-C30 and ERA-G5
Description: use endovenous radiofrequency closure catheter (ERA-C70,ERA-C30) and endovenous radiofrequency closure generator (ERA-G5) to treat varicose veins of lower extremity
Study NCT04658901 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ClosureFast™ and ClosureRFG™
Description: use ClosureFast™ and ClosureRFG™ which has the indication of the treatment of varicose veins of lower extremity approved by NMPA
Study NCT06120400 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Whole Egg
Description: Whole Large, Grade A Egg
Study NCT06120400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole Egg
Description: Whole Large, Grade A Egg
Study NCT05068466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: Administered Orally
Study NCT05068466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered Orally
Study NCT06360250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human anti-tetanus toxin monoclonal antibody A82 / B86 injection combination preparation
Description: Each dose (1.0 ml) contained 1.25 mg of human anti-tetanus toxin monoclonal antibody A82 and 1.25 mg of human anti-tetanus toxin monoclonal antibody B86.
Study NCT06360250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus human immunoglobulin (HTIG)
Description: Tetanus human immunoglobulin (HTIG)
Study NCT06360250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Whole-human anti-tetanus toxin monoclonal antibody A82 / B86 injection placebo
Description: There were no active ingredients, and other ingredients were the same
Study NCT06360250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adsorbed tetanus vaccine (TT)
Description: containing tetanus toxoid titer not less than 40 IU
Study NCT06360250 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adsorbed tetanus vaccine (TT)
Description: containing tetanus toxoid titer not less than 40 IU
Study NCT06360250 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adsorbed tetanus vaccine (TT)
Description: containing tetanus toxoid titer not less than 40 IU
Study NCT05279248 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV+MMR（0d），HPV（6m）
Description: Simultaneously administrated with MMR vaccine and HPV 16/18 bivalent vaccine at first. And six months later, administrated with the second dose of HPV 16/18 bivalent vaccine.
Study NCT05279248 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HPV（0d），HPV（6m），MMR（7m）
Description: Administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (0,6 months).And at the 7th month , administrated with MMR vaccine.
Study NCT05279248 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR（0d），HPV（1m），HPV（7m）
Description: Administrated with MMR vaccine at first day. And administrated with HPV 16/18 bivalent vaccine according to 2-dose schedule (1,7 months).
Study NCT06474949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine injection
Description: Injection at end of Open Reduction Internal Fixation
Study NCT06474949 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Injection at end of Open Reduction Internal Fixation
Study NCT06001658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Patients will receive treatment on Day 1 and Day 8 of each cycle. Gemcitabine (1000 mg/m2) will be administered IV on Day 1 and Day 8 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery.
Study NCT06001658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients will receive treatment on Day 1 and Day 8 of each cycle. Cisplatin (25 mg/m2) will be administered IV on Day 1 and Day 8 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery.
Study NCT06001658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive treatment on Day 1 of each cycle. Pembrolizumab (200 mg) will be administered IV on Day 1 of each cycle, Q3 weeks with 2 - 4 cycles prior to surgery and then 4-6 cycles after surgery. Pembrolizumab (400 mg) will be administered IV Q6 weeks up to 4 cycles as maintenance.
Study NCT05839275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: In phase Ib: 250mg, 200mg, d1-21，qd; In phase II: recommended phase 2 dose (RP2D), d1-21，qd.
Study NCT05839275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 200mg, d1, q3w
Study NCT05839275 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: BED=50-60Gy (α/β=10); Radiation dose depends on tumor characteristics and organs at risk.~Starts at the begin of the second cycle of systemic therapy (week 4 of the therapy).
Study NCT04544475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Revaree
Description: Hyaluronic Acid Vaginal Insert (Revaree). A 2g vaginal insert that contains 5mg of HLA sodium salt and a base of semi-synthetic glycerides. It is an insert that does not require an applicator and should be placed in the vagina while laying down twice weekly.
Study NCT04544475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrace
Description: Vaginal estrogen cream, estradiol: 100mcg
Study NCT05125055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab (anti-programmed death-1 inhibitor)
Description: The participants will receive two cycles of Toripalimab, with 21 days each. 240mg of Toripalimab will be used intravenously on the first day of each cycle.
Study NCT05125055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel
Description: The participants will receive two cycles of Albumin paclitaxel, with 21 days each. 260mg/m\^2 of Albumin paclitaxel will be used intravenously on the first day of each cycle.
Study NCT05125055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: The participants will receive two cycles of Cisplatin, with 21 days each. 75mg/m\^2 of Cisplatin will be used intravenously on the first day of each cycle.
Study NCT05125055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: The participants will receive two cycles of Cisplatin, with 21 days each. 75mg/m\^2 of Cisplatin will be used intravenously on the first day of each cycle.
Study NCT05125055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: The participants will receive two cycles of Docetaxel, with 21 days each. 75mg/m\^2 of Docetaxel will be used intravenously on the first day of each cycle.
Study NCT05125055 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: The participants will receive two cycles of 5-Fluorouracil, with 21 days each. 750mg/m\^2/d of 5-Fluorouracil will be used as a 120-hour continuous intravenous infusion on days 1 through 5.
Study NCT05168800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialogue-Based Webinar
Description: One-time virtual webinars facilitated by a long-term care worker and a physician expert. The webinars will include provision of the existing COVID-19 vaccine Option Grid(TM) conversation aid. The majority of time will be focused on answering participants' questions about COVID-19 and the COVID-19 vaccines. An additional refresher intervention will be delivered several weeks later that will comprise of an email with links to a pre-recorded, shorter webinar available in video and audio-only formats.
Study NCT05168800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Website
Description: A curated COVID-19 social media website. The website will feature content from different social media platforms. The posts will include information about COVID-19 and the COVID-19 vaccines. Participants will have the ability to like and comment on website content and can re-visit the website as many times as they like. An additional refresher intervention will be delivered several weeks later that will comprise of an email featuring previews and links to a selection of website content.
Study NCT05168800 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Practice
Description: COVID-19 vaccine information on the Centers for Disease Control and Prevention (CDC) website. An additional refresher will be delivered several weeks later that will comprise of an email with a link to the COVID-19 vaccine information on the CDC website.
Study NCT05445375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAD education video
Description: 20-min online multi-media video
Study NCT05523037 — intervention group
Intervention type: DRUG
Intervention: Sevoflurane
Description: For the maintenance of anesthesia, the end-tidal concentration of 1 minimum alveolar concentration (MAC) sevoflurane and the concentration was adjusted by 1% stepwise titration
Study NCT05523037 — intervention group
Intervention type: DRUG
Intervention: Remimazolam
Description: For the maintenance of anesthesia, 1-2 mg.kg-1.h-1 of remimazolam was continuously infused.
Study NCT04702802 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate 3%
Description: During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.
Study NCT04702802 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sodium hyaluronate 3%
Description: During intraocular surgery phacoemulsification and intraocular lens implantation, patients with age-related cataract will be exposed to injection of viscoelastic device in the anterior chamber, allowing the procedure to take place.
Study NCT04629820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Intervention group workers receive free glasses within one week of undergoing vision assessment (September 2021). The assessment period will be three months
Study NCT04697238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Weight vest
Description: A vest weighing up to a maximum of 15 kg.
Study NCT04697238 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Weight vest
Description: A vest weighing up to a maximum of 15 kg.
Study NCT05984342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Adjuvant Chemotherapy （nab-paclitaxel 260mg/m2 d1 plus Cisplatin 75mg/m2 d1 or 25mg/m2 d1-3) in combination with Tislelizumab (200 mg Q3W)
Study NCT05153083 — intervention group
Intervention type: PROCEDURE
Intervention: Open thoracic (TAA) and thoracoabdominal aortic aneurysms repair (TAAA)
Description: Each participating center will be able to use its preferred European Conformity marked device, for cryoablation according to their normal clinical practice and according to the instructions for use.
Study NCT05991635 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gatekeeper training (e-learning)
Description: The gatekeeper training consists of an interactive e-learning (min. 1h, max. 3h) which includes theoretical knowledge, tips, exercises and relevant examples and cases. The main topics included in the e-learning are:~* Background information on suicide in Flanders (rates)~* Definitions and theoretical background (suicidal process, integrative explanatory model of suicide)~* Debunking existing myths about suicide~* The role of the pharmacist in suicide prevention~* Signal Recognition~* Talking about suicide and suicidal thoughts (start the conversation)~* How and to whom to refer as pharmacist or FTA~* Medication management and medication in the context of suicide~* Rights and obligations of a pharmacist/PTA in the context of suicide prevention~* Self-care
Study NCT06338904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-solving-based psychological intervention
Description: The intervention will include training in the components of the problem-solving model and other behavioral and cognitive skills such as detecting warning signals, monitoring mood, relaxation techniques, self-reinforcement, strategies for acting in crisis situations, engaging in enjoyable activities, mindfulness meditation techniques, or strategies for reframing irrational thoughts. It will be developed from the problem-solving model (D'Zurilla and Nezu, 1982) and will reference the indicated prevention program for depression (Vázquez et al., 2015), which has shown efficacy in reducing depressive symptoms and preventing the onset of depression episodes (Otero et al., 2015; Vázquez et al., 2013), with results on symptomatology maintained at 8 years (López et al., 2020); and the indicated prevention intervention that demonstrated efficacy in reducing suicide risk (Xavier et al., 2019).
Study NCT04755075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Subjects to receive Surufatinib 250 mg on Day 1
Study NCT05503173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCBMAP
Description: MCBMAP integrates motivational interviewing (MI) and cognitive-behavioral skill training interventions for unhealthy drinking with cognitive-behavioral and self- management approaches for chronic pain. The intervention is delivered through internet-based videoconferencing and supplemented with web-based content to support the intervention. The initial treatment session provides a rationale for addressing alcohol and pain together in the context of HIV management, and initiates MI related to alcohol use. Participants receive 6 additional treatment sessions over the subsequent weeks.
Study NCT05503173 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief Advice and Information
Description: Through videoconferencing an interventionist will provide participants psychoeducation about the effects of alcohol and pain on HIV symptoms, advice/recommendations to reduce alcohol use, and a list of local treatment resources for alcohol and chronic pain.
Study NCT04438161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PERCCS: Personalized Education Regarding Clinical and Community Supports
Description: A brief follow-up to the screening provided to 50% of the consented families (randomly assigned) that links their specific familial risks to community interventions.
Study NCT04438161 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PERCCS: Personalized Education Regarding Clinical and Community Supports
Description: A brief follow-up to the screening provided to 50% of the consented families (randomly assigned) that links their specific familial risks to community interventions.
Study NCT06092554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LactoLevure
Description: Patients will receive two capsules, twice daily for 30 days, one through the nasogastric tube and one spread on the oropharynx. The probiotic capsules look identical to the placebo capsules; the powder will be similar when opened. The capsule for nasogastric tube will be opened and suspended in 100 ml of tap water. The capsule for the oropharynx will be opened and suspended in sterile water based surgical lubricant. The administration must happen at least 30 minutes after oral antiseptic product usage (e.g. daily chlorhexidine oral care), which otherwise might neutralize the study supplement's action.